Trial reportRespiratory research2025
A randomized trial of continuous positive airway pressure for the asthma of obesity.
Trial report in Respiratory research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02953431 (Increased Lung Volume as Controller Therapy for Asthma), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Increased Lung Volume as Controller Therapy for Asthma
Who cites it
1 citing paper in PubMed.
- Commenting on "a randomized trial of continuous positive airway pressure for the asthma of obesity" by Anne E. Dixon and colleagues.Respiratory research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPeople with obesity and asthma often experience poor asthma control and frequent exacerbations, and exhibit airway hyperresponsiveness (AHR) that may be mitigated by elevating lung volume. Our objective was to determine if nocturnal continuous positive airway pressure (CPAP) mitigates AHR in people with obesity, both with and without asthma.
methodsWe performed a double-blinded randomized controlled trial at two centers. Participants with BMI ≥ 30 kg/m2 with (n = 20) and without (n = 20) asthma were randomized to 7 nights of CPAP of 10 cmH2O or sham CPAP (4 cmH2O). Baseline airway physiology and response to methacholine were measured by oscillometry before and after CPAP intervention. Airway responsiveness was quantified by PC100AX - the concentration of methacholine producing a 100% increase in the area under the reactance curve, and also by the concentration response change in R5 and AX at the peak concentration of methacholine.
resultsThe change in resistance at 19 Hz improved numerically in controls assigned to CPAP 10 cmH2O versus sham (-0.29 ± 0.08 versus − 0.07 ± 0.31 H2O.s.L−1, p = 0.07). AHR to methacholine was reduced numerically in controls assigned to CPAP 10 cmH2O versus sham, with the mean PC100AX (SD) being 0.43 (0.64) versus − 0.87 (0.64) mg/ml, p = 0.17. There was a modest difference in the change in the R5 concentration response in controls with CPAP 10 versus sham (median (IQ range): -0.55 (-1.14, 0.05) versus 0.31 (-0.20, 0.51), p = 0.04). CPAP 10 cmH2O versus sham did not change lung function or airway responsiveness in participants with asthma, but there was a trend toward an ameliorating effect in individuals with obesity alone.
conclusionsAHR in obese asthma is not simply related to the mechanical effects of obesity causing a reduction in lung volume. Subclinical abnormalities in airway responsiveness in people with obesity but without asthma might improve with nocturnal CPAP.
trial registrationThis study was registered on clinicaltrials.gov (NCT02953431, last update June 21, 2024).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.